An interventional study of Levothyroxine Sodium (LT4) Tablets in Thyroid Function, Preterm and SGA and Growth, sponsored by Shandong Provincial Hospital. Not yet recruiting at 1 site in China. Open to participants aged 2 Weeks to 2 Weeks. Per ClinicalTrials.gov, last updated 2026-06-04.
Sponsored by Shandong Provincial Hospital · Not applicable, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 79 studies in Premature Birth with a site in China — 26 open to participants now, 31 under way, 2 of them phase 3. Premature Birth · China.
Among the 79 studies in Premature Birth with a site in China, this one is the 33rd largest by planned enrollment of the 44 interventional ones that give a count, is one of 10 that started in 2026, is one of 25 with no phase, reaches primary completion later than 18 of the 30 other live ones, and was the 75th registered.
2,557 studies on the registry are indexed under Premature Birth; 504 are open to participants now.
Browse Premature Birth studies →26 of the 79 studies in Premature Birth with a site in China are open now. Recruiting first, the newest first:
Shanghai Jiao Tong University School of Medicine · Sites in China
Ages 0 days+
Guangzhou Women and Children's Medical Center · Sites in China
Ages up to 12 mo
Children's Hospital of Fudan University · Sites in China
Ages up to 1 days
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University · Sites in China
Ages 1 min–1 hrs
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine · Sites in China
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 318 Premature Birth studies recruiting now, 88 (28%) set no upper age limit and 226 (71%) stop at 75 or younger; 243 take children under 18; 104 take healthy volunteers.
This study: 2 Weeks to 2 Weeks · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
79 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 7 · Phase 3 5 · Phase 4 8
First in 2006; this study’s year is marked. 10 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 106 is above the median of 84 across 1,670 interventional studies indexed under Premature Birth.
Median enrollment 195 across the 44 interventional studies, 541 across the 35 observational. Of the 31 that completed or were terminated, 1 (3%) have results posted.
This tab as a report to print or save as PDF → With an account.
4 of 79 have an industry lead sponsor. The 10 most frequent:
Shandong Provincial Hospital is the lead sponsor of 64 studies on the registry; 26 are open to participants now.
Shandong Provincial Hospital has 1 study filed under Premature Birth — fewer than ten, so there is no comparison to draw.
9 of the studies in Premature Birth with a site in China that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03168516Phase 3University Hospital TuebingenEffects of Closed-loop Automatic Control of FiO2 in Extremely Preterm Infants | 2026-12 |
| NCT06414655Peking University Third HospitalMulticenter Prospective Cohort Study of Twin Maternal-Child Dyads in China | 2026-11-30 |
| NCT07756177Sun Yat-sen UniversityGuangzhou Preterm and Term Birth Cohort Study | 2026-12-31 |
| NCT06234332Peking UniversityPeking University Birth Cohort in Weifang (PKUBC-WF) | 2026-12-31 |
| NCT04777760Daping Hospital and the Research Institute of Surgery of the Third Military Medical UniversitySurfactant for Neonatal Respiratory Distress Syndrome(NRDS) and Neonatal Acute Respiratory Distress Syndrome(NARDS) | 2026-12-31 |
Add all 9 to your calendar (.ics) → With an account.
Among the 79 studies in Premature Birth with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The primary objective of this clinical trail is to evaluate whether early supplementation of levothyroxine (L-T4) at a dosage of 8 ug/kg/d, initiated in the second week of life, improves physical growth and neurodevelopmental outcomes at 2 years of corrected age in Small for Gestational Age (SGA) infants with birth weights \< 1500g and TSH levels between 6 and 20 mIU/ml. Preterm infants in the intervention group will receive 8 ug/kg/d of L-T4, while the control group will receive no supplementation. Physical growth will be assessed through height, weight, and head circumference, while neurodevelopmental status will be evaluated using the Bayley-IV scales and cranial MRI imaging findings.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Levothyroxine Sodium (LT4) Tablets
The intervention group will receive oral levothyroxine (L-T4) initiated on postnatal day 14 at a starting dose of 8 ug/kg/day. Thyroid function will be monitored every 2-4 weeks until 36 weeks postmenstrual age or hospital discharge, with subsequent follow-up at corrected ages of 40 weeks, 3, 6, 12, 18, and 24 months. The L-T4 dosage will be dynamically titrated to achieve therapeutic targets of TSH \< 5 mIU/L and FT3/FT4 levels within the upper 50% of the age-specific reference range. Treatment will be discontinued if therapeutic targets are sustained at a dosage below 2 ug/kg/day or if FT3/FT4 levels exceed the upper limit of normal.
Cognitive function evaluated by Bayley-IV
Time frame: At 24 months corrected age
Motor function evaluated by Bayley-IV
Time frame: At 24 months corrected age
Language function evaluated by Bayley-IV
Time frame: At 24 months corrected age
Social-Emotional evaluated by Bayley-IV
Time frame: At 24 months corrected age
Adaptive behavior evaluated by Bayley-IV
Time frame: At 24 months corrected age
Body length(cm)assessed by the WHO 0-5 years Child Growth Standards.
Time frame: At 24 months corrected age
Head circumference(cm)assessed by the WHO 0-5 years Child Growth Standards.
Time frame: At 24 months corrected age
Weight(kg)assessed by the WHO 0-5 years Child Growth Standards.
Time frame: At 24 months corrected age
the incidence of neonatal morbidities (EUGR、PNAC、MBDP、Moderate to severe BPD、Stage III or higher ROP)during the initial hospitalization
Time frame: at 36 weeks of postmenstrual age
All-cause Mortality
Time frame: At 24 months corrected age
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Jun 2026; primary completion for Jun 2027, 12 months later.
Of 746 non-industry interventional studies with no phase under Premature Birth, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 47. This study's planned 12 months is below that.
Counting every sponsor, half of 764 studies reached it within 24 months; a quarter within 12 and three quarters within 47.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Thyroxine
Shandong Provincial Hospital